Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch

Piramal Pharma Solutions Italy India United Kingdom

This significant milestone demonstrates the facility's advanced capabilities, operational efficiency, and technical expertise. With this achievement, Piramal strengthens its leadership position in delivering critical bioconjugate therapies to patients in need.| LinkedIn| Facebook | X

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: Piramal Pharma | LinkedIn

Photo: https://mma.prnewswire.com/media/2934422/Piramal_Grangemouth_team.jpg
Logo: https://mma.prnewswire.com/media/1726186/Piramal_Pharma_Solutions_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-solutions-grangemouth-uk-facility-successfully-delivers-1-500th-adc-batch-302714493.html